Trial Profile
Cost-effectiveness analysis (CEA) between erlotinib and gefitinib for patients with advanced non-small cell lung cancer (NSCLC) in Thailand.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Aug 2011
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 03 Aug 2011 New trial record